Related Experiment Video
Updated: Feb 9, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Treatment of patients with peritoneal metastases from gastric cancer
Joji Kitayama1, Hironori Ishigami2, Hironori Yamaguchi1
1Department of Gastrointestinal Surgery Jichi Medical University Shimotsuke Japan.
Abstract:
Despite recent advances in chemotherapy, outcomes of patients with peritoneal metastases (PM) from gastric cancer are still very poor and standard treatment has not been established. Although oral S-1 appears to be effective for patients with PM, the effects of systemic chemotherapy are limited. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) yield fewer benefits in patients with PM from gastric cancer than in patients with PM from other malignancies. In comparison, repeated intraperitoneal chemotherapy (RIPEC) with taxanes using an implantable peritoneal access port has a pharmacokinetic advantage for the control of peritoneal lesions and in combination with systemic chemotherapy can result in surprisingly long-term survival in patients with PM from gastric cancer. Herein, we review the results of recent clinical studies specifically targeting PM from gastric cancer and discuss future prospects for an intraperitoneal approach to the ideal treatment of patients with gastric cancer with peritoneal involvement.
Related Concept Videos
Treatment Resistant Cancers
Gastric Emptying
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Gastric Phase of Digestion
When food enters the stomach, it stretches the stomach walls and activates stretch receptors. This triggers local reflexes of the enteric nervous system, mediated through the myenteric plexus. These...
Peritoneal Dialysis I: Introduction and Procedure

